MYH7B
ENSG00000078814
Target class
Unclassified protein
Chromosome
20
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- MYH7B
- Gene name
- Myosin heavy chain 7B
- Gene symbol
- MYH7B
- Protein name
- Myosin-7B (Antigen MLAA-21) (Myosin cardiac muscle beta chain) (Myosin heavy chain 7B, cardiac muscle beta isoform) (Slow A MYH14)
- KIAA1512
- dJ756N5.1
- MYH14
- MHC14
- lncMYH7b
- Gene biotype
- Protein coding
- Gene family
- Myosin heavy chains, class II|MicroRNA protein coding host genes
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 42
- Highest tissue expression
- 78.51
- Tissue specificity (Gini)
- 0.668
- Tissue specificity (tau)
- 0.944
- KEGG gene identifiers
- hsa:57644
- End position
- 35002437
- Start position
- 34955810
- Chromosome
- 20
- Strand
- Forward
- Membrane
- Peripheral membrane protein .
Publication evidence
- PubMed 15755502
- Tissue specificity (tau)
- 0.944057
- Expression inequality (Gini)
- 0.668486
Expression in transcripts per million
- Heart - Left Ventricle
- 78.51
- Heart - Atrial Appendage
- 49.42
- Testis
- 32.75
- Muscle - Skeletal
- 9.47
- Brain - Spinal cord (cervical c-1)
- 8.78
Expression in transcripts per million
- Heart - Left Ventricle78.51
- Heart - Atrial Appendage49.42
- Testis32.75
- Muscle - Skeletal9.47
- Brain - Spinal cord (cervical c-1)8.78
- Brain - Frontal Cortex (BA9)7.7
- Brain - Cortex7.61
- Brain - Cerebellar Hemisphere7.23
- Brain - Cerebellum6.97
- Brain - Substantia nigra6.26
- Nerve - Tibial6.17
- Brain - Hippocampus4.77
- Brain - Hypothalamus4.68
- Ovary4.64
- Brain - Putamen (basal ganglia)4.58
- Brain - Caudate (basal ganglia)4.47
- Thyroid4.35
- Cervix - Ectocervix4.23
- Brain - Amygdala4.14
- Pituitary4.12
- Brain - Anterior cingulate cortex (BA24)4.05
- Uterus3.77
- Brain - Nucleus accumbens (basal ganglia)2.99
- Fallopian Tube2.94
- Cervix - Endocervix2.93
And 29 more, listed on the interactive page.
Molecular functions
- GO:0005515
Related records
Trials (65)
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
- A Pharmacokinetic and Pharmacodynamic Study of Omecamtiv Mecarbil in Healthy Volunteers
- A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
- A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
- A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
- A Study of CK-1827452 Infusion in Stable Heart Failure
- A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
- A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
- A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
- A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
- A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure
- A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants
- A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
- A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants
- A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- A Study to Assess the Treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) With Mavacamten in the US
- A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Drugs (3)
- Danicamtiv Cardiac myosin activator
- Mavacamten Cardiac myosin inhibitor
- Omecamtiv mecarbil Cardiac myosin activator